Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab replacement after progression on first-line immunotherapy plus anti-angiogenic therapy in advanced hepatocellular carcinoma
ChiCTR2400080364Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: objective response rate and duration of response. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400080364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080364.